Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Change in Accured Expenses: 2017-2024

Historic Change in Accured Expenses for Kiniksa Pharmaceuticals International (KNSA) over the last 8 years, with Dec 2024 value amounting to $43.7 million.

  • Kiniksa Pharmaceuticals International's Change in Accured Expenses fell 22.49% to $8.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.9 million, marking a year-over-year decrease of 24.09%. This contributed to the annual value of $43.7 million for FY2024, which is 158.14% up from last year.
  • Kiniksa Pharmaceuticals International's Change in Accured Expenses amounted to $43.7 million in FY2024, which was up 158.14% from $16.9 million recorded in FY2023.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Change in Accured Expenses ranged from a high of $43.7 million in FY2024 and a low of -$3.7 million during FY2022.
  • Moreover, its 3-year median value for Change in Accured Expenses was $16.9 million (2023), whereas its average is $19.0 million.
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Change in Accured Expenses crashed by 135.87% in 2022 and then skyrocketed by 556.73% in 2023.
  • Yearly analysis of 5 years shows Kiniksa Pharmaceuticals International's Change in Accured Expenses stood at $8.8 million in 2020, then rose by 17.53% to $10.3 million in 2021, then tumbled by 135.87% to -$3.7 million in 2022, then spiked by 556.73% to $16.9 million in 2023, then spiked by 158.14% to $43.7 million in 2024.